文献速递细菌感染、耐药与抗菌药物医院感染防控

碳青霉烯耐药革兰阴性菌感染的治疗选择

Treatment Options for Carbapenem-resistant Gram-negative Bacterial Infections.
PubMed 文献 · Clin Infect Dis · 2019-01-01

综述指出碳青霉烯耐药革兰阴性菌感染治疗选择有限,黏菌素和替加环素虽为一线但疗效不确定;近年获批或晚期研发的新药包括头孢他啶-阿维巴坦、头孢洛扎-他唑巴坦、美罗培南-伐硼巴坦、亚胺培南-西司他丁-瑞来巴坦、普拉佐米星、依拉环素和头孢地尔,另有磷霉素静脉新剂型;新药临床数据逐渐出现且总体优于既往最佳治疗,抗菌药物管理对合理使用至关重要。

要点

  • 碳青霉烯耐药革兰阴性菌涵盖肠杆菌科、铜绿假单胞菌、鲍曼不动杆菌和嗜麦芽窄食单胞菌。
  • 黏菌素和替加环素一线使用疗效不确定,即使联合用药。
  • 新药临床数据总体支持优于既往最佳治疗,需加强抗菌药物管理。

核心结论

  • 碳青霉烯耐药革兰阴性菌感染治疗选择有限,新药临床数据逐渐出现且总体优于既往最佳治疗,抗菌药物管理对合理使用新药至关重要。

研究设计与样本

  • 综述,检索范围未在摘要中报告。

主要发现

  • 黏菌素和替加环素作为一线药物治疗碳青霉烯耐药革兰阴性菌感染,即使联合其他药物,疗效仍存在不确定性。
  • 新药包括头孢他啶-阿维巴坦、头孢洛扎-他唑巴坦、美罗培南-伐硼巴坦、亚胺培南-西司他丁-瑞来巴坦、普拉佐米星、依拉环素和头孢地尔,已获批或处于晚期临床研发。
  • 磷霉素被重新开发为新的静脉制剂。
  • 针对碳青霉烯耐药病原体感染的新药临床疗效数据逐渐出现,总体倾向于新药优于既往最佳治疗。

临床怎么用

  • 临床面对碳青霉烯耐药革兰阴性菌感染时,可考虑新药作为治疗选择,并需结合抗菌药物管理确保合理使用。

局限性

  • 摘要未报告综述的检索范围、纳入标准及新药的具体疗效数值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Antimicrobial resistance has become one of the greatest threats to public health, with rising resistance to carbapenems being a particular concern due to the lack of effective and safe alternative treatment options. Carbapenem-resistant gram-negative bacteria of clinical relevance include the Enterobacteriaceae, Pseudomonas aeruginosa, Acinetobacter baumannii, and more recently, Stenotrophomonas maltophilia. Colistin and tigecycline have been used as first-line agents for the treatment of infections caused by these pathogens; however, there are uncertainties regarding their efficacy even when used in combination with other agents. More recently, several new agents with activity against certain carbapenem-resistant pathogens have been approved for clinical use or are reaching late-stage clinical development. They include ceftazidime-avibactam, ceftolozane-tazobactam, meropenem-vaborbactam, imipenem-cilastatin-relebactam, plazomicin, eravacycline, and cefiderocol. In addition, fosfomycin has been redeveloped in a new intravenous formulation. Data regarding the clinical efficacy of these new agents specific to infections caused by carbapenem-resistant pathogens are slowly emerging and appear to generally favor newer agents over previous best available therapy. As more treatment options become widely available for carbapenem-resistant gram-negative infections, the role of antimicrobial stewardship will become crucial in ensuring appropriate and rationale use of these new agents.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Doi Y. Treatment Options for Carbapenem-resistant Gram-negative Bacterial Infections. Clin Infect Dis. 2019. PMID: 31724043. doi:10.1093/cid/ciz830

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。